Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Intec Pharma (NTEC) Share Price
Headlines about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intec Pharma earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.0315960496304 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news articles that may have effected Accern’s rankings:
- Zacks Investment Research Upgrades Intec Pharma Ltd. (NTEC) to “Buy” (americanbankingnews.com)
- FY2017 Earnings Forecast for Intec Pharma Ltd. (NTEC) Issued By Oppenheimer Holdings (americanbankingnews.com)
- -$0.19 EPS Expected for Intec Pharma Ltd. (NTEC) This Quarter (americanbankingnews.com)
- Intec Pharma Ltd. (NTEC) PT Set at $15.00 by Oppenheimer Holdings, Inc. (americanbankingnews.com)
- 4 Active Shares Moving Down Today – VIAB, AXGN, DPLO, NTEC (fxpips.com)
NTEC has been the subject of a number of research analyst reports. ValuEngine downgraded Intec Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Zacks Investment Research upgraded Intec Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Oppenheimer Holdings, Inc. set a $15.00 price objective on Intec Pharma and gave the company a “buy” rating in a research report on Friday, October 13th. Roth Capital set a $10.00 target price on Intec Pharma and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, CIBC reaffirmed an “outperform” rating and issued a $15.00 price target (up from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $11.00.
Intec Pharma (NTEC) remained flat at $$6.05 during trading on Friday. The company’s stock had a trading volume of 426,400 shares, compared to its average volume of 44,298. Intec Pharma has a fifty-two week low of $4.20 and a fifty-two week high of $9.80.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Intec Pharma (NTEC) Share Price” was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-intec-pharma-ntec-share-price/1724428.html.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.